Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.
Immune B-cells May Aid in Predicting HER2+ Breast Cancer Treatment miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.